It has recently been shown that HER2 can demonstrate mutations in about 1.8 % of diverse cancers (∼7300 solid tumor specimens tested) and that rearrangements can be seen, albeit very rarely (∼0.02 % of patients) [44]. This evidence concerns the gene ERBB2 and cancer.